Cardiff Oncology (CRDF) Stock Price Target 2026

The average analyst price target for Cardiff Oncology is $8.93, 1023.3% above the current price. Of 7 analysts, 3 rate it Buy and 4 Hold. Targets range from $2 to $19. The latest change came on Sep 15, 2026, when HC Wainwright & Co. upgraded Cardiff Oncology from Neutral to Buy with a $9 price target.

The Average Analyst Price Target for Cardiff Oncology is $8.93.

Price Target Range — 10 Quarters

Analyst Consensus — 7 Analysts

3Buy

4Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$8.93Upside to Avg. PT+1023.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Cardiff Oncology Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	HC Wainwright & Co.	Robert Burns	Upgrade	Neutral→Buy	$9
Aug 12, 2026	William Blair	Andy Hsieh	Downgrade	Outperform→Market Perform	—
Jun 3, 2026	Craig-Hallum	Albert Lowe	Downgrade	Buy→Hold	$10→$2
Jun 1, 2026	TD Cowen	Marc Frahm	Downgrade	Buy→Hold	—
Jun 1, 2026	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	—
Feb 25, 2026	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$10→$6
Jan 28, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$10
Aug 6, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$18→$10
Jul 8, 2025	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$19
Jun 24, 2025	Jefferies	Maury Raycroft	Initiate	Hold	$4
May 9, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$17→$18
Feb 28, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$13→$17
Dec 13, 2024	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$7→$10
Nov 8, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$14→$13
Sep 6, 2024	Craig-Hallum	Albert Lowe	Initiate	Buy	$8
May 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$14
Mar 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$12→$14
Mar 1, 2024	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$5→$7